Neeraj Sharma, MD
Nephrology · Los Angeles, CANPI 1316294341
Payments from drug & device makers
Across 14 payments — averaging $926.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$11K
- Amgen$1K
- Inari Medical, Inc.$236
- Mallinckrodt Hospital Products Inc.$190
- Veloxis Pharmaceuticals, Inc.$127
- Ferring Pharmaceuticals Inc.$22
What the payments were for
- Consulting fees$734%
- Speaking & faculty fees$1,32867%
- Food & beverage$46423%
- Education$1286%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $10,984 |
| Amgen | 4 | $1,419 |
| Inari Medical, Inc. | 1 | $236 |
| Mallinckrodt Hospital Products Inc. | 2 | $190 |
| Veloxis Pharmaceuticals, Inc. | 4 | $127 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$1,328
- FLOWTRIEVER CATHETER, S$236
- CT THROMBECTOMY SYSTEM KIT$236
- UVADEX$118
How this compares
$12,978 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 68 | $54,761 |
| VeltassaPatiromer Calcium Sorbitex | 40 | $37,243 |
| JardianceEmpagliflozin | 41 | $32,040 |
| OzempicSemaglutide | 36 | $31,349 |
| EliquisApixaban | 44 | $24,723 |
| FarxigaDapagliflozin Propanediol | 32 | $20,493 |
| Cinacalcet Hcl | 73 | $20,444 |
| KerendiaFinerenone | 20 | $16,285 |
| TradjentaLinagliptin | 21 | $14,271 |
| Valganciclovir Hcl | 65 | $14,001 |
| HorizantGabapentin Enacarbil | 20 | $10,470 |
| Sevelamer Hcl | 13 | $5,652 |
| Mycophenolate Mofetil | 37 | $5,205 |
| Tacrolimus | 26 | $5,040 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $4,572 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.